Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Angelo Belotti, Barbara Frittoli, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Chiara Saeli, Samantha Ferrari, Annalisa Peli, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Carmela Carbone, Alessandro Gullino, Marco Chiarini, Viviana Giustini, Aldo Roccaro, Luigi Grazioli, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 82.

https://doi.org/10.1182/blood-2024-198779

Published: 2024

Journal Articles

Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis

Mirko Farina, Marco Chiarini, Sofia Terlizzi, Anna Galvagni, Simona Bernardi, Alessandro Leoni, Enrico Morello, Vera Radici, Gabriele Magliano, Lorenzo Masina, Marco Galli, Federica Re, Virginia Quaresima, Daniele Moratto, Duilio Brugnoni, Michele Malagola, Nicola Polverelli, Domenico Russo

Blood (2024) 144 (Supplement 1): 7372.

https://doi.org/10.1182/blood-2024-209545

Published: 2024

Journal Articles

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Blood (2024) 144 (Supplement 1): 453.

https://doi.org/10.1182/blood-2024-203258

Published: 2024

Journal Articles

Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients

Blood (2023) 142 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2023-184455

Published: 2023

Journal Articles

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Blood (2023) 142 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2023-188408

Published: 2023

Journal Articles

The Use of Next Generation Flow in Multiple Myeloma Patients: A Preliminary Real-Life Multicenter MRD Harmonization Experience

Blood (2023) 142 (Supplement 1): 7161.

https://doi.org/10.1182/blood-2023-186536

Published: 2023

Journal Articles

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Blood (2023) 141 (21): 2615–2628.

https://doi.org/10.1182/blood.2022019240

Published: 2023

Includes: Supplemental data

Journal Articles

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Angelo Belotti, Rossella Ribolla, Claudia Crippa, Marco Chiarini, Viviana Giustini, Samantha Ferrari, Annalisa Peli, Chiara Cattaneo, Aldo Roccaro, Barbara Frittoli, Marta Salis, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2022) 140 (Supplement 1): 1140–1141.

https://doi.org/10.1182/blood-2022-157520

Published: 2022

Journal Articles

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Angelo Belotti, Rossella Ribolla, Alberta Villanacci, Marco Chiarini, Viviana Giustini, Giulia Vittoria Facchetti, Claudia Crippa, Valeria Cancelli, Samantha Ferrari, Annalisa Peli, Chiara Bottelli, Chiara Cattaneo, Chiara Saeli, Aldo M. Roccaro, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2021-147694

Published: 2021

Journal Articles

External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry

Angelo Belotti, Rossella Ribolla, MD, Valeria Cancelli, MD, Alberta Villanacci, Valentina Angelini, Samantha Ferrari, Annalisa Peli, MD, Chiara Cattaneo, MD, Marco Chiarini, MSc, Luigi Grazioli, MD, Giuseppe Rossi, MD, Alessandra Tucci, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-135969

Published: 2020

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Angelo Belotti, MD, Rossella Ribolla, Valeria Cancelli, MD, Nicola Bianchetti, Claudia Crippa, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marco Chiarini, Luigi Grazioli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2018-99-113022

Published: 2018

Journal Articles

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, MD, Chiara Cattaneo, MD, Enrico Morello, MD, Vincenza Orlando, PharmD, Nicola Bianchetti, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Francesca Schieppati, MD, Aldo M. Roccaro, Marco Chiarini, Mario Morone, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3161.

https://doi.org/10.1182/blood.V130.Suppl_1.3161.3161

Published: 2017

Journal Articles

Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

Francesca Schieppati, MD, Angela Passi, MD, Erika Borlenghi, MD, Cinzia Lamorgese, Giuseppina Ruggeri, MD, Marco Chiarini, MSc, Viviana Giustini, MSc, Michele Malagola, MD, Chiara Cattaneo, MD, Margherita Sciumé, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3931.

https://doi.org/10.1182/blood.V130.Suppl_1.3931.3931

Published: 2017

Journal Articles

Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk

Marco Chiarini, MSc, Viviana Giustini, MSc, Francesco Buccisano, MD, Erika Borlenghi, MD, Mirko Farina, MD, Chiara Cattaneo, MD, Diego Bertoli, MSc, Federico Serana, MD PhD, Alessandro Montanelli, MD, Luisa Imberti, MD, Aldo M. Roccaro, Maria Ilaria Del Principe, Luca Maurillo, MD, PhD, Adriano Venditti, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 2697.

https://doi.org/10.1182/blood.V130.Suppl_1.2697.2697

Published: 2017

Journal Articles

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

Antonio Sacco, Loredana Affò, Gaia C Ghedini, Gaetana Lanzi, Arianna Giacomini, Marina Motta, Antonella Anastasia, Claudia Ghidini, Marco Chiarini, Silvia Giliani, Roberto Ronca, Luisa Imberti, MD, Alessandro Montanelli, MD, Nicole Bozza, Riccardo Castelli, Giuseppe Rossi, MD, Marco Mor, Marco Presta, Aldo M. Roccaro

Blood (2017) 130 (Supplement 1): 2818.

https://doi.org/10.1182/blood.V130.Suppl_1.2818.2818

Published: 2017

Journal Articles

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Erika Borlenghi, MD, Mirko Farina, MD, Marco Chiarini, MSC, Viviana Giustini, MSC, Cinzia Lamorgese, Angela Passi, MD, Enrico Morello, MD, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2016) 128 (22): 2882.

https://doi.org/10.1182/blood.V128.22.2882.2882

Published: 2016

Journal Articles

Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia

Blood (2016) 127 (21): 2598–2606.

https://doi.org/10.1182/blood-2015-11-680199

Published: 2016

Includes: Supplemental data

Journal Articles

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Marina Motta, MD, Marco Chiarini, MSC, Marta Petullà, PharmD, Claudia Ghidini, BSC, Marion Vaglio Tessitore, BSC, Viviana Giustini, MSC, Chiara Pagani, MD, Antonella Anastasia, MD, Samantha Ferrari, MD, Alessandra Tucci, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 1531.

https://doi.org/10.1182/blood.V126.23.1531.1531

Published: 2015

Journal Articles

Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination

Aldo M Roccaro, MD PhD, Antonio Sacco, BS, Michele Moschetta, MD, Yuji Mishima, PhD, Patricia Maiso, PhD, Daisy Huynh, MPS, Marco Chiarini, MSc, Pina M. Cardarelli, PhD, Lewis Cohen, MD MS, Michelle Kuhne, PhD, Irene M. Ghobrial, MD

Blood (2014) 124 (21): 4709.

https://doi.org/10.1182/blood.V124.21.4709.4709

Published: 2014

NARROW

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

The Use of Next Generation Flow in Multiple Myeloma Patients: A Preliminary Real-Life Multicenter MRD Harmonization Experience

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only